Immunogenic compositions of polysaccharide-protein pegylated compounds
The disclosure describes compositions containing PEGylated compounds using linkers, bivalent polysaccharide covalent PEG compounds, and methods of bivalent polysaccharide-PEG compounds in the development of multivalent vaccines. PEGylated conjugation of capsular polysaccharides to carrier proteins is carried out using homo-bifunctional and/or hetero-bifunctional linkers of specific lengths. Incorporation of bifunctional PEG linkers induces higher titers of functional antibodies with high avidity, eliciting higher immunologic memory, and reduced carrier protein effect. This provides immunochemically cross-reactive capsular polysaccharides wherein one or more cross-reactive capsular polysaccharides are covalently PEG compounded sequentially or concurrently to carrier protein using bifunctional linkers bearing the same or different functional groups. Such a linker and the size of the capsular polysaccharides provides an effective multivalent vaccine with high antibody titers and a reduced carrier effect, with a reduction in the content of the capsular polysaccharide and protein per dose of vaccine which reduces reactogenicity.
1. A method for protection against an infection by Streptococcus pneumoniae comprising:
providing an immunogenic composition comprising a first group of monovalent capsular polysaccharides and a second group of bivalent or multivalent capsular polysaccharides wherein:
the first group of monovalent capsular polysaccharides comprise polysaccharides of S. pneumoniae serotypes 1, 2, 3, 4, 5, 7F, 8, 10A, 11A, 12F, 14, 17F, 18C, 20, 22F, 23F, 24F, 33F and 35B; and
the second group of bivalent or multivalent capsular polysaccharides comprising two or more polysaccharides selected from one or more of the groups consisting of S. pneumoniae serotypes 6A/6B/6C/6D, S. pneumoniae serotypes 9V/9N/9A/9B, S. pneumoniae serotypes 15B/15A/15C, and S. pneumoniae serotypes 19A/19F, wherein:
the first group of monovalent capsular polysaccharides are each covalently coupled to a first PEG linker which is couple to a first carrier protein, and
the second group of bivalent or multivalent capsular polysaccharides are each covalently coupled to a second PEG linker which is coupled to a second carrier protein; and
administering a dose of the immunogenic composition to a subject.
2. The method of claim 1 , wherein the bivalent or multivalent capsular polysaccharides comprises two immunologically cross-reactive serotypes of S. pneumoniae.
3. The method of claim 1 , wherein the second group of bivalent or multivalent capsular polysaccharides comprises a structure polysaccharide-PEG-carrier protein-PEG-polysaccharide.
4. The method of claim 1 , wherein the bivalent or multivalent capsular polysaccharides covalently coupled to the second PEG linker are covalently coupled to the second carrier protein sequentially or concurrently.
5. The method of claim 1 , wherein the first group of monovalent capsular polysaccharides and/or the second group of bivalent or multivalent capsular polysaccharides comprise capsular polysaccharides of from about 10 kDa to about 50 kDa, from about 30 KDa to about 100 KDa, and/or from about 100 KDa to about 300 KDa.
6. The method of claim 1 , wherein the second group of bivalent or multivalent capsular polysaccharides comprise the structure 6A-PEG-CRM197-PEG-6B.
7. The method of claim 1 , wherein the first carrier protein and/or the second carrier protein comprises tetanus toxoid, diphtheria toxoid, CRM197, tetanus toxoid fragments (TTHc), Neisseria meningitidis protein PorB, RSV virus proteins, Bordetella pertussis proteins, Pertussis toxoid (PT), adenylate cyclase toxin (ACT), 69 KDa protein of Hepatitis B virus, Human Papilloma viral protein antigens, Human Papilloma virus virus-like particle (VLP) forms, Hepatitis B virus core antigen, Hepatitis B virus VLP forms, Hepatitis B virus surface antigen (HBsAg), and/or combinations thereof.
8. The method of claim 1 , wherein the immunogenic composition comprises 4 micrograms or less of total polysaccharides per dose.
9. The method of claim 1 , wherein the first carrier protein and the second carrier protein of the immunogenic composition comprises from about 0.5% to about 0.8% by weight.
10. The method of claim 1 , wherein the immunogenic composition comprises about equal amounts by weight of capsular polysaccharides to total carrier protein.
11. The method of claim 1 , wherein the immunogenic composition comprises a greater amount by weight of capsular polysaccharides compared to total carrier protein.
12. The method of claim 1 , wherein the immunogenic composition further comprises at least one adjuvant.
13. The method of claim 12 , wherein the adjuvant is selected from the group consisting of aluminum salt, calcium phosphate, a liposome of monophosphoryl lipid A (MPLA), saponin QS-21, a TLR7/8 agonist, and combinations thereof.
14. The method of claim 13 , wherein the aluminum salt is selected from the group consisting of aluminum phosphate, aluminum sulfate and aluminum hydroxide.
15. The method of claim 1 , wherein the subject is a human.
16. The method of claim 15 , wherein the human is a child or an infant.
17. A method for protection against an infection by Streptococcus pneumoniae comprising:
providing an immunogenic composition comprising a first group of monovalent capsular polysaccharides and a second group of bivalent or multivalent capsular polysaccharides wherein:
the first group of monovalent capsular polysaccharides comprise polysaccharides of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 7F, 8, 10A, 11A, 12F, 14, 17F, 18C, 20, 22F, 23F, 24F, 33F and 35B; and
the second group of bivalent or multivalent capsular polysaccharides comprising two or more polysaccharides selected from one or more of the groups consisting of S. pneumoniae serotypes 6A, 6B, 6C, and 6D, S. pneumoniae serotypes 9A, 9B, 9N, and 9V, S. pneumoniae serotypes 15A, 15B, and 15C, and S. pneumoniae serotypes 19A and 19F; wherein,
polysaccharides of S. pneumoniae serotypes 6A, 6B, 6C, 6D, 9A, 9B, 9N, 9V, 15A, 15B, 15C, 19A, and 19F that are not included in the second group are included in the first group:
the first group of monovalent capsular polysaccharides are each covalently coupled to a first PEG linker which is coupled to a first carrier protein, and
the second group of bivalent or multivalent capsular polysaccharides are each covalently coupled to a second PEG linker which is coupled to a second carrier protein; and
administering the composition to a subject.
18. The method of claim 17 , wherein the first group of monovalent capsular polysaccharides comprise polysaccharides of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 7F, 8, 10A, 11A, 12F, 14, 15A, 15B, 15C, 17F, 18C, 19A, 19F 20, 22F, 23F, 24F, 33F and 35B, and the second group of bivalent or multivalent capsular polysaccharides comprises polysaccharides of S. pneumoniae serotypes 6A, 6B, 6C, 6D, 9A, 9B, 9N, and 9V.
19. The method of claim 17 , wherein the first group of monovalent capsular polysaccharides comprise polysaccharides of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 7F, 8, 9A, 9B, 9N, 9V, 10A, 11A, 12F, 14, 17F, 18C, 19A, 19F, 20, 22F, 23F, 24F, 33F and 35B, and the second group of bivalent or multivalent capsular polysaccharides comprises polysaccharides of S. pneumoniae serotypes 6A, 6B, 6C, 6D, 15A, 15B, and 15C.
20. The method of claim 17 , wherein the first group of monovalent capsular polysaccharides comprise polysaccharides of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 7F, 8, 9A, 9B, 9N, 9V, 10A, 11A, 12F, 14, 15A, 15B, 15C, 17F, 18C, 20, 22F, 23F, 24F, 33F and 35B, and the second group of bivalent or multivalent capsular polysaccharides comprises polysaccharides of S. pneumoniae serotypes 6A, 6B, 6C, 6D, 19A, and 19F.
21. The method of claim 17 , wherein the first group of monovalent capsular polysaccharides comprise polysaccharides of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 6C, 6D, 7F, 8, 10A, 11A, 12F, 14, 17F, 18C, 19A, 19F, 20, 22F, 23F, 24F, 33F and 35B, and the second group of bivalent or multivalent capsular polysaccharides comprises polysaccharides of S. pneumoniae serotypes 9A, 9B, 9N, 9V, 15A, 15B, and 15C.
22. The method of claim 17 , wherein the first group of monovalent capsular polysaccharides comprise polysaccharides of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 6C, 6D, 7F, 8, 10A, 11A, 12F, 14, 15A, 15B, 15C, 17F, 18C, 20, 22F, 23F, 24F, 33F and 35B, and the second group of bivalent or multivalent capsular polysaccharides comprises polysaccharides of S. pneumoniae serotypes 9A, 9B, 9N, 9V, 19A, and 19F.
23. The method of claim 17 , wherein the first group of monovalent capsular polysaccharides comprise polysaccharides of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 6C, 6D, 7F, 8, 9A, 9B, 9N, 9V, 10A, 11A, 12F, 14, 17F, 18C, 20, 22F, 23F, 24F, 33F and 35B, and the second group of bivalent or multivalent capsular polysaccharides comprises polysaccharides of S. pneumoniae serotypes 15A, 15B, 15C, 19A, and 19F.
24. The method of claim 17 , wherein the first group of monovalent capsular polysaccharides comprise polysaccharides of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 7F, 8, 10A, 11A, 12F, 14, 17F, 18C, 20, 22F, 23F, 24F, 33F and 35B, and the second group of bivalent or multivalent capsular polysaccharides comprises polysaccharides of S. pneumoniae serotypes 6A, 6B, 6C, 6D, 9A, 9B, 9N, 9V, 15A, 15B, 15C, 19A, and 19F.
25. The method of claim 17 , wherein the first group of monovalent capsular polysaccharides and/or the second group of bivalent or multivalent capsular polysaccharides comprise capsular polysaccharides of from about 10 kDa to about 50 kDa, from about 30 KDa to about 100 KDa, and/or from about 100 KDa to about 300 KDa.
26. The method of claim 17 , wherein the immunogenic composition comprises 4 micrograms or less of total polysaccharides per dose.
27. The method of claim 17 , wherein the first carrier protein and the second carrier protein of the immunogenic composition comprises from about 0.5% to about 0.7% by weight.
28. The method of claim 17 , wherein the immunogenic composition comprises about equal amounts by weight of capsular polysaccharides to total carrier protein.
29. The method of claim 17 , wherein the immunogenic composition comprises a greater amount by weight of capsular polysaccharides compared to total carrier protein.
30. The method of claim 17 , wherein the subject is a human.
31. The method of claim 30 , wherein the human is a child or an infant.